Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs AT&T Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.01 (market cap $29.60B), while AT&T Inc. trades at $24.25 (market cap $167.88B). The key difference: AT&T Inc. is far larger — about 5.7× Alnylam Pharmaceuticals, Inc.'s market cap, and AT&T Inc. pays a 4.53% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | T | |
|---|---|---|
Market Cap | $29.60B | $167.88B |
Sector | Health | Media |
52-Week High | $491.22 | $29.62 |
52-Week Low | $205.48 | $20.49 |
Enterprise Value | $27.56B | $313.20B |
Dividend Yield | — | 4.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
AT&T (T) trades at $24.25, up 0.73% today, with a bullish technical signal from moving averages but overbought RSI near 77. The stock shows strong fundamentals with a P/E of 8.09, net income margin of 16.94%, and consistent earnings beats in recent quarters. Recent news highlights fiber expansion and AI partnerships, while cash flow improved to $15.12B in 2025.
Outlook is positive with a consensus price target of $27.69, offering 14% upside, supported by dividend yield near 4.7%. Risks include competition from SpaceX's Starlink and high debt levels. Analysts are mixed with 41% buy ratings, suggesting cautious optimism for value investors seeking income and steady growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
